166 related articles for article (PubMed ID: 25019406)
1. Benzhydrylpiperazine compounds inhibit cholesterol-dependent cellular entry of hepatitis C virus.
Chamoun-Emanuelli AM; Pécheur EI; Chen Z
Antiviral Res; 2014 Sep; 109():141-8. PubMed ID: 25019406
[TBL] [Abstract][Full Text] [Related]
2. Entry inhibitors and future treatment of hepatitis C.
Fofana I; Jilg N; Chung RT; Baumert TF
Antiviral Res; 2014 Apr; 104():136-42. PubMed ID: 24525381
[TBL] [Abstract][Full Text] [Related]
3. Identification of a series of 1,3,4-trisubstituted pyrazoles as novel hepatitis C virus entry inhibitors.
Hwang JY; Kim HY; Park DS; Choi J; Baek SM; Kim K; Kim S; Seong S; Choi I; Lee HG; Windisch MP; Lee J
Bioorg Med Chem Lett; 2013 Dec; 23(23):6467-73. PubMed ID: 24125883
[TBL] [Abstract][Full Text] [Related]
4. Discovery of highly potent small molecule Hepatitis C Virus entry inhibitors.
Mittapalli GK; Jackson A; Zhao F; Lee H; Chow S; McKelvy J; Wong-Staal F; Macdonald JE
Bioorg Med Chem Lett; 2011 Nov; 21(22):6852-5. PubMed ID: 21978675
[TBL] [Abstract][Full Text] [Related]
5. Activity-based and fraction-guided analysis of Phyllanthus urinaria identifies loliolide as a potent inhibitor of hepatitis C virus entry.
Chung CY; Liu CH; Burnouf T; Wang GH; Chang SP; Jassey A; Tai CJ; Tai CJ; Huang CJ; Richardson CD; Yen MH; Lin CC; Lin LT
Antiviral Res; 2016 Jun; 130():58-68. PubMed ID: 27012176
[TBL] [Abstract][Full Text] [Related]
6. Specific inhibition of hepatitis C virus entry into host hepatocytes by fungi-derived sulochrin and its derivatives.
Nakajima S; Watashi K; Kamisuki S; Tsukuda S; Takemoto K; Matsuda M; Suzuki R; Aizaki H; Sugawara F; Wakita T
Biochem Biophys Res Commun; 2013 Nov; 440(4):515-20. PubMed ID: 24099774
[TBL] [Abstract][Full Text] [Related]
7. Identification of a New Benzimidazole Derivative as an Antiviral against Hepatitis C Virus.
Vausselin T; Séron K; Lavie M; Mesalam AA; Lemasson M; Belouzard S; Fénéant L; Danneels A; Rouillé Y; Cocquerel L; Foquet L; Rosenberg AR; Wychowski C; Meuleman P; Melnyk P; Dubuisson J
J Virol; 2016 Oct; 90(19):8422-34. PubMed ID: 27412600
[TBL] [Abstract][Full Text] [Related]
8. Screening of small-molecule compounds as inhibitors of HCV entry.
Yang JP; Zhou D; Wong-Staal F
Methods Mol Biol; 2009; 510():295-304. PubMed ID: 19009270
[TBL] [Abstract][Full Text] [Related]
9. Methanolic Extract of
Hung TC; Jassey A; Lin CJ; Liu CH; Lin CC; Yen MH; Lin LT
Viruses; 2018 Nov; 10(12):. PubMed ID: 30486350
[TBL] [Abstract][Full Text] [Related]
10. A Novel Class of Small Molecule Compounds that Inhibit Hepatitis C Virus Infection by Targeting the Prohibitin-CRaf Pathway.
Liu S; Wang W; Brown LE; Qiu C; Lajkiewicz N; Zhao T; Zhou J; Porco JA; Wang TT
EBioMedicine; 2015 Nov; 2(11):1600-6. PubMed ID: 26870784
[TBL] [Abstract][Full Text] [Related]
11. [Antiviral activity in vitro and pharmacokinetics of HCV entry inhibitor AVR560].
Ivashchenko AV; Iamanushkin PM; Mit'kin OD; Ezhova EV; Korzinov OM; Bulanova EA; Koriakova AG; Vyshemirskaia PV; Bychko VV; Ivashchenko AA
Eksp Klin Farmakol; 2014; 77(10):38-43. PubMed ID: 25518527
[TBL] [Abstract][Full Text] [Related]
12. Multiple effects of Honokiol on the life cycle of hepatitis C virus.
Lan KH; Wang YW; Lee WP; Lan KL; Tseng SH; Hung LR; Yen SH; Lin HC; Lee SD
Liver Int; 2012 Jul; 32(6):989-97. PubMed ID: 22098176
[TBL] [Abstract][Full Text] [Related]
13. (-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry.
Calland N; Albecka A; Belouzard S; Wychowski C; Duverlie G; Descamps V; Hober D; Dubuisson J; Rouillé Y; Séron K
Hepatology; 2012 Mar; 55(3):720-9. PubMed ID: 22105803
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets for antiviral therapies.
Zeisel MB; Fofana I; Fafi-Kremer S; Baumert TF
J Hepatol; 2011 Mar; 54(3):566-76. PubMed ID: 21146244
[TBL] [Abstract][Full Text] [Related]
15. [Research on hepatitis C virus entry inhibitor].
Zeng Wenting ; Lu X; Wang J; Jin X; Zhu J
Bing Du Xue Bao; 2015 Jan; 31(1):97-105. PubMed ID: 25997338
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of hepatitis C virus infection by polyoxometalates.
Qi Y; Xiang Y; Wang J; Qi Y; Li J; Niu J; Zhong J
Antiviral Res; 2013 Nov; 100(2):392-8. PubMed ID: 24025401
[TBL] [Abstract][Full Text] [Related]
17. Entry inhibitors: New advances in HCV treatment.
Qian XJ; Zhu YZ; Zhao P; Qi ZT
Emerg Microbes Infect; 2016 Jan; 5(1):e3. PubMed ID: 26733381
[TBL] [Abstract][Full Text] [Related]
18. Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor.
Sainz B; Barretto N; Martin DN; Hiraga N; Imamura M; Hussain S; Marsh KA; Yu X; Chayama K; Alrefai WA; Uprichard SL
Nat Med; 2012 Jan; 18(2):281-5. PubMed ID: 22231557
[TBL] [Abstract][Full Text] [Related]
19. Novel small-molecule inhibitors of hepatitis C virus entry block viral spread and promote viral clearance in cell culture.
Coburn GA; Fisch DN; Moorji SM; de Muys JM; Murga JD; Paul D; Provoncha KP; Rotshteyn Y; Han AQ; Qian D; Maddon PJ; Olson WC
PLoS One; 2012; 7(4):e35351. PubMed ID: 22545104
[TBL] [Abstract][Full Text] [Related]
20. Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents.
Conteduca V; Sansonno D; Russi S; Pavone F; Dammacco F
J Infect; 2014 Jan; 68(1):1-20. PubMed ID: 24012819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
